This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Lorecivivint
DrugBank Accession Number
DB14883
Background

Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 505.557
Monoisotopic: 505.202636584
Chemical Formula
C29H24FN7O
Synonyms
  • Lorecivivint
External IDs
  • SM04690

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
42EK42WHI5
CAS number
1467093-03-3
InChI Key
AQDWDWAYVBQMAM-UHFFFAOYSA-N
InChI
InChI=1S/C29H24FN7O/c1-16(2)8-26(38)33-21-10-19(12-31-13-21)17-6-7-24-22(11-17)28(37-36-24)29-34-25-15-32-14-23(27(25)35-29)18-4-3-5-20(30)9-18/h3-7,9-16H,8H2,1-2H3,(H,33,38)(H,34,35)(H,36,37)
IUPAC Name
N-(5-{3-[7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1H-indazol-5-yl}pyridin-3-yl)-3-methylbutanamide
SMILES
CC(C)CC(=O)NC1=CC(=CN=C1)C1=CC2=C(NN=C2C2=NC3=C(C=NC=C3N2)C2=CC=CC(F)=C2)C=C1

References

General References
Not Available
ChemSpider
58810247

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentOsteoarthritis of the Knee1
3CompletedTreatmentOsteoarthritis of the Knee2
3TerminatedTreatmentOsteoarthritis of the Knee1
2CompletedTreatmentOsteoarthritis (OA)1
2CompletedTreatmentOsteoarthritis of the Knee2
2TerminatedTreatmentOsteoarthritis of the Knee1
1CompletedOtherDrug Drug Interaction (DDI)1
1CompletedTreatmentModerate to Severe Osteoarthritis1
1TerminatedTreatmentIntervertebral Disc Degeneration1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00336 mg/mLALOGPS
logP4.52ALOGPS
logP4.66ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)8.46ChemAxon
pKa (Strongest Basic)4.81ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area112.24 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity154.53 m3·mol-1ChemAxon
Polarizability53.54 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at May 20, 2019 14:32 / Updated at February 21, 2021 18:54